Communiqués Prothena Corporation plc

Actions

PRTA

IE00B91XRN20

Temps réel estimé Cboe BZX Autres places de cotation 16:25:55 16/07/2024			Varia. 5j.	Varia. 1 janv.
23,23 ^USD	+2,83 %		+11,55 %	-36,74 %

28/05	Prothena recevra 80 millions de dollars de Bristol-Myers Squibb pour la licence mondiale du PRX019	MT
28/05	Prothena annonce que Bristol Myers Squibb a opté pour une licence mondiale exclusive pour PRX019, le deuxième programme de la collaboration mondiale en recherche et développement dans le domaine des neurosciences	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Prothena : Corporate Overview	29/05	PU
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	28/05	BU
Prothena: Q1 Earnings Snapshot	08/05	AQ
Prothena : Corporate Overview	08/05	PU
Prothena Reports First Quarter 2024 Financial Results and Business Highlights	08/05	BU
Prothena to Report First Quarter 2024 Financial Results on May 8	01/05	BU
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia and Lymphoma	16/04	AQ
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma	15/04	BU
Prothena : Director's Report and Financial Statements for Fiscal Year 2023	29/03	PU
Prothena to Participate in Upcoming Healthcare Conferences	05/03	BU
Prothena Appoints David Ford to Newly Created Chief People Officer Position	04/03	BU
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate	21/02	BU
Prothena: Q4 Earnings Snapshot	15/02	AQ
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights	15/02	BU
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024	08/02	BU
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs	08/01	BU
Prothena: Q3 Earnings Snapshot	02/11	AQ
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights	02/11	BU
Prothena to Report Third Quarter 2023 Financial Results on November 2	26/10/23	BU
AL Amyloidosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)	18/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Prothena Corporation plc

Actions

PRTA

IE00B91XRN20

Communiqués

Filtres